This Article Full Text Full Text (PDF) All Versions of this Article: 2007-0025OCv1 37/6/748    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hodge, S. Articles by Reynolds, P. N. Search for Related Content PubMed PubMed Citation Articles by Hodge, S. Articles by Reynolds, P. N.

Smoking Alters Alveolar Macrophage Recognition and Phagocytic Ability

Implications in Chronic Obstructive Pulmonary Disease

¹ Department of Thoracic Medicine, Royal Adelaide Hospital and Lung Research Laboratory, Hanson Institute, Adelaide, South Australia

Correspondence and requests for reprints should be addressed to Dr. Sandra Hodge, Lung Research, Hanson Institute, Frome Rd, Adelaide, South Australia 5001. E-mail: sandy.hodge{at}imvs.sa.gov.au

Chronic obstructive pulmonary disease (COPD) is associated with defective efferocytosis (apoptosis and alveolar macrophage [AM] phagocytic function) that may lead to secondary necrosis and tissue damage. We investigated ex vivo AM phagocytic ability and recognition molecules (CD36, integrin V3, CD31, CD91, CD44) using flow cytometry. The transferrin receptor (CD71) was measured as an indicator of monocyte-macrophage differentiation in bronchoalveolar lavage (BAL). Proliferation was assessed with Ki-67. Based on evidence of systemic involvement in COPD, blood from 17 current smokers and 25 ex-smokers with COPD, 22 healthy smokers, and 20 never-smoking control subjects was also investigated. BAL was collected from 10 to 16 subjects in each group. Levels of recognition molecules and cAMP were assessed after exposure of AM to cigarette smoke in vitro. The phagocytic ability of AM was significantly decreased in both COPD groups and in healthy smokers compared with control subjects. However, phagocytic capacity was better in subjects with COPD who had ceased smoking, compared with those who were still smoking. AM from current smokers with COPD and healthy smokers exhibited reduced CD31, CD91, CD44, and CD71, and enhanced Ki-67 compared with healthy never-smoker control subjects. There were no differences in these markers in AM from ex-smokers with COPD compared with control subjects, or in blood monocytes from any group. Suppressive effects of cigarette smoke on AM recognition molecules associated with an increase in cAMP were confirmed in vitro. Our data indicates that a smoking-related reduction in AM phagocytic ability and expression of several important recognition molecules may be at least partially normalized in those subjects with COPD who have ceased smoking.

Key Words: cigarette smoke • chronic obstructive pulmonary disease • alveolar macrophage • phagocytosis • cAMP

CLINICAL RELEVANCE Our findings suggest that failed efferocytosis in chronic obstructive pulmonary disease (COPD) is cigarette smoke–related, and may be improved by smoking cessation. Further, our study has highlighted biomarkers that may be targeted as potential new treatment strategies for COPD.

 

This article has been cited by other articles:

				R. Shaykhiev, A. Krause, J. Salit, Y. Strulovici-Barel, B.-G. Harvey, T. P. O'Connor, and R. G. Crystal Smoking-Dependent Reprogramming of Alveolar Macrophage Polarization: Implication for Pathogenesis of Chronic Obstructive Pulmonary Disease J. Immunol., August 15, 2009; 183(4): 2867 - 2883. [Abstract] [Full Text] [PDF]

				T. R. Richens, D. J. Linderman, S. A. Horstmann, C. Lambert, Y.-Q. Xiao, R. L. Keith, D. M. Boe, K. Morimoto, R. P. Bowler, B. J. Day, et al. Cigarette Smoke Impairs Clearance of Apoptotic Cells through Oxidant-dependent Activation of RhoA Am. J. Respir. Crit. Care Med., June 1, 2009; 179(11): 1011 - 1021. [Abstract] [Full Text] [PDF]

				G. J. Gaschler, M. Skrtic, C. C. J. Zavitz, M. Lindahl, P.-O. Onnervik, T. F. Murphy, S. Sethi, and M. R. Stampfli Bacteria Challenge in Smoke-exposed Mice Exacerbates Inflammation and Skews the Inflammatory Profile Am. J. Respir. Crit. Care Med., April 15, 2009; 179(8): 666 - 675. [Abstract] [Full Text] [PDF]

				C Herr, C Beisswenger, C Hess, K Kandler, N Suttorp, T Welte, J-M Schroeder, C Vogelmeier, and R B. f. t. C. S. Group Suppression of pulmonary innate host defence in smokers Thorax, February 1, 2009; 64(2): 144 - 149. [Abstract] [Full Text] [PDF]

				T. Walser, X. Cui, J. Yanagawa, J. M. Lee, E. Heinrich, G. Lee, S. Sharma, and S. M. Dubinett Smoking and Lung Cancer: The Role of Inflammation Proceedings of the ATS, December 1, 2008; 5(8): 811 - 815. [Abstract] [Full Text] [PDF]

				A. Kazeros, B.-G. Harvey, B. J. Carolan, H. Vanni, A. Krause, and R. G. Crystal Overexpression of Apoptotic Cell Removal Receptor MERTK in Alveolar Macrophages of Cigarette Smokers Am. J. Respir. Cell Mol. Biol., December 1, 2008; 39(6): 747 - 757. [Abstract] [Full Text] [PDF]

				C. H. Serezani, M. N. Ballinger, D. M. Aronoff, and M. Peters-Golden Cyclic AMP: Master Regulator of Innate Immune Cell Function Am. J. Respir. Cell Mol. Biol., August 1, 2008; 39(2): 127 - 132. [Abstract] [Full Text] [PDF]

				S. Hodge, G. Hodge, H. Jersmann, G. Matthews, J. Ahern, M. Holmes, and P. N. Reynolds Azithromycin Improves Macrophage Phagocytic Function and Expression of Mannose Receptor in Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., July 15, 2008; 178(2): 139 - 148. [Abstract] [Full Text] [PDF]

				K. F. Chung and I. M. Adcock Multifaceted mechanisms in COPD: inflammation, immunity, and tissue repair and destruction Eur. Respir. J., June 1, 2008; 31(6): 1334 - 1356. [Abstract] [Full Text] [PDF]